Literature DB >> 16236550

The clinical immunology of human Chagas disease.

Walderez O Dutra1, Manoel Otávio C Rocha, Mauro M Teixeira.   

Abstract

Human infection with the protozoan parasite Trypanosoma cruzi leads to Chagas disease, which affects approximately 17 million people in Latin America. A significant percentage of the infected population will develop clinical symptoms or present changes in laboratory and/or image evaluation. The existence of a large spectrum of clinical manifestations--with patients ranging from asymptomatic to severe cardiac involvement--emphasizes the need to use standardized and well-defined clinical criteria among different research groups. In this article, we carry out a systematic review of the immunology in human Chagas disease, discussing recent findings in the context of a clinical perspective.

Entities:  

Mesh:

Year:  2005        PMID: 16236550     DOI: 10.1016/j.pt.2005.09.007

Source DB:  PubMed          Journal:  Trends Parasitol        ISSN: 1471-4922


  33 in total

1.  Clinical aspects of Chagas disease and implications for novel therapies.

Authors:  Cristiane Menezes; Germano Carneiro Costa; Kenneth J Gollob; Walderez O Dutra
Journal:  Drug Dev Res       Date:  2011-09       Impact factor: 4.360

2.  New drugs for neglected infectious diseases: Chagas' disease.

Authors:  Fabiana S Machado; Herbert B Tanowitz; Mauro M Teixeira
Journal:  Br J Pharmacol       Date:  2010-05       Impact factor: 8.739

3.  Highly conserved CDR3 region in circulating CD4(+)Vβ5(+) T cells may be associated with cytotoxic activity in Chagas disease.

Authors:  C A S Menezes; A K Sullivan; M T Falta; D G Mack; B M Freed; M O C Rocha; K J Gollob; A P Fontenot; W O Dutra
Journal:  Clin Exp Immunol       Date:  2012-08       Impact factor: 4.330

Review 4.  Current concepts in immunoregulation and pathology of human Chagas disease.

Authors:  Walderez O Dutra; Kenneth J Gollob
Journal:  Curr Opin Infect Dis       Date:  2008-06       Impact factor: 4.915

5.  Pharmacokinetics of Benznidazole in Experimental Chronic Chagas Disease Using the Swiss Mouse-Berenice-78 Trypanosoma cruzi Strain Model.

Authors:  Suzana Marques de Jesus; Leonardo Pinto; Fernanda de Lima Moreira; Glauco Henrique Balthazar Nardotto; Rodrigo Cristofoletti; Luísa Perin; Kátia da Silva Fonseca; Pauliana Barbêdo; Lorena Cera Bandeira; Paula Melo de Abreu Vieira; Claudia Martins Carneiro
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

Review 6.  Diagnosis and management of Chagas disease and cardiomyopathy.

Authors:  Antonio L Ribeiro; Maria P Nunes; Mauro M Teixeira; Manoel O C Rocha
Journal:  Nat Rev Cardiol       Date:  2012-07-31       Impact factor: 32.419

7.  Trypanosoma cruzi infection induces differential modulation of costimulatory molecules and cytokines by monocytes and T cells from patients with indeterminate and cardiac Chagas' disease.

Authors:  Paulo E A Souza; Manoel O C Rocha; Cristiane A S Menezes; Janete S Coelho; Andréa C L Chaves; Kenneth J Gollob; Walderez O Dutra
Journal:  Infect Immun       Date:  2007-02-05       Impact factor: 3.441

8.  Cyclic AMP decreases the production of NO and CCL2 by macrophages stimulated with Trypanosoma cruzi GPI-mucins.

Authors:  Andre Talvani; Sibele Ferreira Coutinho; Luciola da Silva Barcelos; Mauro Martins Teixeira
Journal:  Parasitol Res       Date:  2008-12-18       Impact factor: 2.289

9.  Does cyclophosphamide play a protective role against neuronal loss in chronic T. cruzi infection?

Authors:  Leony Cristina Caetano; Sérgio Zucoloto; Laura Midori Kawasse; Miriam Paula Alonso Toldo; José Clóvis do Prado
Journal:  Dig Dis Sci       Date:  2008-04-22       Impact factor: 3.199

10.  Characterising the KMP-11 and HSP-70 recombinant antigens' humoral immune response profile in chagasic patients.

Authors:  Ivonne D Flechas; Adriana Cuellar; Zulma M Cucunubá; Fernando Rosas; Víctor Velasco; Mario Steindel; María del Carmen Thomas; Manuel Carlos López; John Mario González; Concepción Judith Puerta
Journal:  BMC Infect Dis       Date:  2009-11-25       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.